Novara Therapeutics

What Novara Therapeutics does

Novara Therapeutics is a UK-based early-stage biotechnology company founded in 2020 and headquartered in Marylebone, United Kingdom. Per its firmographic profile, the company positions itself in bone imaging and therapeutics, targeting the orthopaedic and bone disease treatment space. The company is private, small-scale (1-10 employees per available data), and operates without a disclosed product portfolio, pricing model, or customer base. Its only documented capital event is a 2020 funding engagement with Embryo Ventures and Orthopaedic Research UK, a specialist orthopaedic research charity, with no disclosed monetary raise.

No management team, board composition, technology stack, or partnership network is disclosed in available sources. There is no product pipeline information, no regulatory filings, no patent portfolio, and no clinical or preclinical program details. The company lacks any public-facing operational signals — no social media profiles, no active customer relationships, no investor disclosures beyond the single 2020 round, and no commercial milestones.

A critical concern across the data set is the status of the company's primary web presence. The domain novaratherapeutics.com, originally registered on 5 August 2020, has expired and is listed for resale on GoDaddy's marketplace for $195 USD. Wayback Machine archives show only four indexed pages and ten crawls, with the first archive snapshot dating to 2022. Combined with the absence of any operational, hiring, or funding activity since 2020, these signals are consistent with an entity that is either pre-operational, dormant, or in effective cessation. Investment diligence should verify the company's actual operating status, as the available evidence does not support an active, going-concern business.

Name

Novara Therapeutics

Website

https://novaratherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Novara Therapeutics is a UK-based early-stage biotechnology company founded in 2020 in Marylebone, focused on bone imaging and therapeutics. The company shows minimal operational activity beyond seed-stage support from Embryo Ventures and Orthopaedic Research UK, with no products or revenue documented.

Ownership category

akta.pro rank

Product category

Bone Imaging and Therapeutics (Biotechnology)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Bone imaging
• Bone therapeutics
• Orthopaedic research
• Biotechnology development
• Medical imaging

Headquarters

HQ city

Marylebone

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D

Core offering

Novara Therapeutics is an early-stage biotechnology company focused on pioneering bone imaging and therapeutics. It develops diagnostic imaging and therapeutic approaches related to bone health and orthopaedic conditions.

Product overview

No product information available. The source data is from ExpiredDomains.com showing the expired domain novaratherapeutics.com for sale at $195 USD, not an active company website with product offerings.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights1 record

Broad incumbents

• Hologic: Hologic operates one of the leading bone density imaging franchises through its DXA (dual-energy X-ray absorptiometry) systems and related women's health diagnostics. Comparable for the bone imaging side of Novara's stated positioning as a specialized bone imaging modality provider.
• LifeNet Health: LifeNet Health is one of the largest suppliers of allograft-based orthobiologics for bone, tendon, and wound healing applications, serving orthopedic and spine surgeons. Comparable as an established orthobiologics incumbent in Novara's therapeutic category.
• Lantheus Holdings: Lantheus is a US-listed radiopharmaceutical company specializing in diagnostic imaging agents (DEFINITY, Neurolite, POINT Biologics) and is actively expanding into therapeutic radiopharmaceuticals. Comparable for an imaging-led platform extending into therapy, analogous to Novara's positioning.
• Bayer (Xofigo / bone radiopharmaceutical franchise): Bayer's pharma division markets Xofigo (radium-223 dichloride), the leading approved bone-targeted radiotherapeutic, alongside imaging support. It is the dominant commercial incumbent in bone radiotherapeutics and a benchmark for the clinical/commercial upside of a bone theranostics program.

Direct peers

• Bone Therapeutics: Bone Therapeutics is a Belgian-listed clinical-stage cell therapy company developing bone-forming cell-based therapies for orthopedic conditions (e.g., osteonecrosis, fracture non-union). It is the most directly comparable named peer given the shared focus on novel bone-targeted therapeutics.
• Kuros Biosciences: Kuros Biosciences is a Swiss-listed orthobiologics company developing bone graft substitutes (including its MagnetOs synthetic bone graft) for spinal fusion and trauma indications. Comparable as a public pure-play in the bone graft substitute space where Novara's therapeutics focus would sit.

Emerging players

• Telix Pharmaceuticals: Telix Pharmaceuticals is a listed radiopharmaceuticals company that pairs molecular imaging agents (e.g., Illuccix for PSMA imaging) with a growing radiotherapeutic pipeline. The combined imaging-plus-therapy model closely mirrors Novara's stated 'Bone Imaging and Therapeutics' (theranostics) positioning.
• Curium Pharma: Curium is one of the largest dedicated radiopharmaceutical manufacturers globally, producing diagnostic imaging tracers (e.g., PET agents used in bone oncology imaging) and a growing therapeutic pipeline. Comparable as a peer bridging radiopharma imaging with emerging therapy.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/novara-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novara Therapeutics